Study identifier:DC-990-0165
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Canadian, Multicenter, Double-Blind, Randomized, Parallel-Group Study of the Safety, Tolerability, and Efficacy of Treatment with Higher Doses of Quetiapine Fumarate (Seroquel®) greater than 800 mg/day in Schizophrenic or Schizoaffective Subjects.
schizophrenia
Phase 3
No
Quetiapine
All
330
Interventional
18 Years - 65 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Mar 2009 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|